FIGURE 3.

Total number and types of cardiovascular (CV) and haematological events reported following COVID‐19 vaccination in 98 included studies, excluding that by Smadja et al. The results of the study by Pottegård et al. are included where events are reported and excluded from cases. A total of 158 CV and haematological events were reported in 122 individuals who received Pfizer vaccine, some of whom suffered from multiple events (50 cardiac injury (CI), 45 thrombosis, 43 thrombocytopenia (TP), 9 haemorrhage and 11 others, including 8 stage 2 hypertension (HTN) and 3 microangiopathy). A total of 45 cases experienced CV and haematological events following receiving Moderna vaccine (25 CI and 17 TP without thrombosis, 1 hemorrhage and 2 others, including 1 stage 2 HTN and 1 hypertensive crisis). Two hundred and seventeen individuals who received AstraZeneca vaccine experienced 747 CV and haematological events as some of them suffered from multiple events (74 cardiac problems, 375 thrombosis, 206 TP and 92 haemorrhage). Sixty‐one events were experienced by 21 individuals who received the J&J vaccine (1 cardiac, 40 thrombosis and 20 TP). A total of two cases experienced CV and haematological events following receiving CoronaVac vaccine (1 Kounis Syndrome, Type I variant and 1 haemophagocytic lymphohistiocytosis). As several individuals experienced multiple events, (A) illustrates the total number of events reported under each category while (B) illustrates the number of individuals who experienced each type of event, regardless of the number of events that each individual had under the same category. However, the categories may overlap as some cases had more than one event from the other major categories presented in the figures